working party on health systems luxembourg 26th april 2005 euro med stat monitoring expenditure and utilisation of medicinal products in the eu member states a public approach pietro folino gallo md rome italy national research council behalf group impact medicines risk adverse drug reactions medication errors economic burden environmental therapeutic benefit available information no up to date european registry licensed data collection using different methodologies standard sources who oecd eurostat do not publish from market agencies ims are publicly quality is uncertain industry oriented commission d g biomed programme & cee consumer protection directorate db objectives 1 establish an inventory survey 2 assess reliability comparability between countries 3 develop set indicators library
